Dr. habil. nat. Iduna Fichtner
studied pharmacy in Jena and Halle and acquired several qualifications in the
field of experimental pharmacology. She has been working in oncology since 1977.
Until 1991 she was department leader at the Central Institute for Cancer
Research of Academy of Sciences; since 1992 she is employed as senior scientist
and head of the group "Experimental Pharmacology" at the Max-Delbrück-Center for
Molecular Medicine. Additionally, she has been responsible for Technology
Transfer of that institution between 1998 and 2002.
Her main research field is the preclinical evaluation and development of novel
potential cancerostatics. For that purpose, several new in vivo models,
especially for leukaemias, breast and colon carcinomas were established and
characterised for clinic-relevance and equipment with molecular targets.
Iduna Fichtner has special expertise for pharmacological investigations
concerning liposomal and other vesicular drugs, and for the study of immuno- and
gene-therapeutics.
The definition of growth and engraftment conditions for normal and leukaemic
stem cells were another focus of her scientific work.
She has published more than 100 original articles in peer reviewed journals.
Mrs. Fichtner is member of the German Cancer Foundation, the European
Organisation for Research and Treatment of Cancer (EORTC) and the American
Association for Cancer Research (AACR). Within the EORTC she was elected for
three years as chairperson of Screening and Pharmacology Group and is presently
speaker of the joint initiative for the development of NCI/EORTC/CRUK derived
anticancer agents.
Further on, she is member of the Central European Society for Anticancer Drug
Research (CESAR)-EWIV and within that organization the head of the Working Group
of New Drug Development in Oncology (AWO).
She is member of the Editorial Board of the AACR journal Molecular Cancer
Tharapeutics.
Copyright © 2007 of EPO GmbH - All rights reserved. 04. März 2008.